Praxis Precision Medicines Inc
NASDAQ:PRAX

Watchlist Manager
Praxis Precision Medicines Inc Logo
Praxis Precision Medicines Inc
NASDAQ:PRAX
Watchlist
Price: 44.3 USD -1.62% Market Closed
Market Cap: 902.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

PRAX Price Targets Summary
Praxis Precision Medicines Inc

Wall Street analysts forecast PRAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRAX is 101.26 USD with a low forecast of 28.28 USD and a high forecast of 283.5 USD.

PRAX Lowest Forecast
Wall Street Target
28.28 USD
36% Downside
PRAX Average Forecast
Wall Street Target
101.26 USD
129% Upside
PRAX Highest Forecast
Wall Street Target
283.5 USD
540% Upside
Lowest
Price Target
28.28 USD
36% Downside
Average
Price Target
101.26 USD
129% Upside
Highest
Price Target
283.5 USD
540% Upside
Praxis Precision Medicines Inc Competitors:
Price Targets
PAR
Paradigm Biopharmaceuticals Ltd
181% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
16% Downside
ACAD
ACADIA Pharmaceuticals Inc
26% Upside
NIOX
Niox Group PLC
18% Upside
PAR
Paradigm Biopharmaceuticals Ltd
181% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
16% Downside
ACAD
ACADIA Pharmaceuticals Inc
26% Upside
NIOX
Niox Group PLC
18% Upside
MNKD
MannKind Corp
183% Upside
CRNX
Crinetics Pharmaceuticals Inc
138% Upside
PHARM
Pharming Group NV
545% Upside
N
4893
Noile-Immune Biotech Inc
161% Upside

Revenue
Forecast

Revenue Estimate
Praxis Precision Medicines Inc

The compound annual growth rate of Praxis Precision Medicines Inc's revenue for the next 3 years is 78%.

N/A
Past Growth
78%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Praxis Precision Medicines Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Praxis Precision Medicines Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-85%
Average Miss
What are analyst estimates?

See Also

Summary
PRAX intrinsic value, competitors valuation, and company profile.
DCF Valuation
PRAX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PRAX stock valuation using valuation multiples.
Wall Street Estimates
PRAX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PRAX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRAX's stock price target?
Price Target
101.26 USD

According to Wall Street analysts, the average 1-year price target for PRAX is 101.26 USD with a low forecast of 28.28 USD and a high forecast of 283.5 USD.

What is Praxis Precision Medicines Inc's Revenue forecast?
Projected CAGR
78%

The compound annual growth rate of Praxis Precision Medicines Inc's revenue for the next 3 years is 78%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.